Mapharsen, or 3-amino-4-hydroxyphenylarsine oxide, a trivalent arsenical preparation originally studied by Ehrlich and Bertheim, Voegtlin and others, was recently again investigated by Tatum and Cooper,1 of the department of pharmacology and toxicology of the University of Wisconsin, and the findings indicated that the drug had properties which warranted its extensive clinical trial in the treatment of syphilis.
The drug was then intensively studied by our group as to its clinical effects, and a preliminary report2 covering a period of eighteen months' experience with mapharsen was presented in June 1933. While this included observations on the effects of the drug on 233 persons, 41 of whom had conditions other than syphilis, detailed observations in 80 cases of syphilis constituted the main body of the report. To obtain at the outset an accurate appraisal of the drug it was used alone in most of the 80 cases.
WIEDER LM, FOERSTER OH, FOERSTER HR. MAPHARSEN IN THE TREATMENT OF SYPHILIS: FURTHER EXPERIENCES. Arch Derm Syphilol. 1937;35(3):402–413. doi:https://doi.org/10.1001/archderm.1937.01470210028003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: